Mostrar el registro sencillo del ítem

dc.contributor.authorVillasanta-González, Alejandro
dc.contributor.authorAlcalá Díaz, Juan Francisco
dc.contributor.authorVals-Delgado, Cristina
dc.contributor.authorArenas, Antonio Pablo
dc.contributor.authorCardelo, Magdalena P.
dc.contributor.authorRomero-Cabrera, Juan Luis
dc.contributor.authorRodríguez-Cantalejo, Fernando
dc.contributor.authorDelgado-Lista, Javier
dc.contributor.authorMalagón, María M.
dc.contributor.authorPérez-Martínez, Pablo
dc.contributor.authorSchulze, Matthias B.
dc.contributor.authorCamargo García, A.
dc.contributor.authorLópez-Miranda, José
dc.date.accessioned2021-11-02T11:54:43Z
dc.date.available2021-11-02T11:54:43Z
dc.date.issued2021
dc.identifier.urihttp://hdl.handle.net/10396/22010
dc.description.abstractPurpose: The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. For this reason, it is essential to identify biomarkers for the early detection of T2DM risk and/or for a better prognosis of T2DM. We aimed to identify a plasma fatty acid (FA) profile associated with T2DM development. Methods: We included 462 coronary heart disease patients from the CORDIOPREV study without T2DM at baseline. Of these, 107 patients developed T2DM according to the American Diabetes Association (ADA) diagnosis criteria after a median follow-up of 60 months. We performed a random classification of patients in a training set, used to build a FA Score, and a Validation set, in which we tested the FA Score. Results: FA selection with the highest prediction power was performed by random survival forest in the Training set, which yielded 4 out of the 24 FA: myristic, petroselinic, α-linolenic and arachidonic acids. We built a FA Score with the selected FA and observed that patients with a higher score presented a greater risk of T2DM development, with an HR of 3.15 (95% CI 2.04–3.37) in the Training set, and an HR of 2.14 (95% CI 1.50–2.84) in the Validation set, per standard deviation (SD) increase. Moreover, patients with a higher FA Score presented lower insulin sensitivity and higher hepatic insulin resistance (p < 0.05). Conclusión: Our results suggest that a detrimental FA plasma profile precedes the development of T2DM in patients with coronary heart disease, and that this FA profile can, therefore, be used as a predictive biomarker.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rightshttps://creativecommons.org/licenses/by/4.0/es_ES
dc.sourceEuropean Journal of Nutrition 61, 843-857 (2022)es_ES
dc.subjectType 2 diabeteses_ES
dc.subjectDisease predictiones_ES
dc.subjectFatty acidses_ES
dc.subjectCOXes_ES
dc.subjectFA Scorees_ES
dc.titleA plasma fatty acid profile associated to type 2 diabetes development: from the CORDIOPREV studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1007/s00394-021-02676-zes_ES
dc.relation.projectIDGobierno de España. AGL2014-53417-Res_ES
dc.relation.projectIDGobierno de España. PCIN-2016-084es_ES
dc.relation.projectIDGobierno de España. PIE14/00005es_ES
dc.relation.projectIDGobierno de España. PIE14/00031es_ES
dc.relation.projectIDGobierno de España. AGL2015-67896-Pes_ES
dc.relation.projectIDGobierno de España. CP14/00114es_ES
dc.relation.projectIDGobierno de España. DTS19/00007es_ES
dc.relation.projectIDInstituto de Salud Carlos III. PI13/00023es_ES
dc.relation.projectIDInstituto de Salud Carlos III. PI19/00299es_ES
dc.relation.projectIDInstituto de Salud Carlos III. PI16/01777es_ES
dc.relation.projectIDJunta de Andalucía. CVI-7450es_ES
dc.relation.projectIDInstituto de Salud Carlos III. CP14/00114es_ES
dc.relation.projectIDInstituto de Salud Carlos III. CPII19/00007es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem